- Home
- PALI vs ARTL Comparison
PALI vs ARTL Comparison
Compare PALI & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PALI
- ARTL
- Stock Information
- Founded
- PALI 1996
- ARTL 2011
- Country
- PALI United States
- ARTL United States
- Employees
- PALI N/A
- ARTL N/A
- Industry
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- ARTL Biotechnology: Pharmaceutical Preparations
- Sector
- PALI Health Care
- ARTL Health Care
- Exchange
- PALI Nasdaq
- ARTL Nasdaq
- Market Cap
- PALI 3.2M
- ARTL 3.6M
- IPO Year
- PALI N/A
- ARTL N/A
- Fundamental
- Price
- PALI $0.72
- ARTL $0.95
- Analyst Decision
- PALI Strong Buy
- ARTL Strong Buy
- Analyst Count
- PALI 2
- ARTL 2
- Target Price
- PALI $23.00
- ARTL $5.50
- AVG Volume (30 Days)
- PALI 71.2K
- ARTL 1.2M
- Earning Date
- PALI 05-12-2025
- ARTL 05-12-2025
- Dividend Yield
- PALI N/A
- ARTL N/A
- EPS Growth
- PALI N/A
- ARTL N/A
- EPS
- PALI N/A
- ARTL N/A
- Revenue
- PALI N/A
- ARTL N/A
- Revenue This Year
- PALI N/A
- ARTL N/A
- Revenue Next Year
- PALI N/A
- ARTL N/A
- P/E Ratio
- PALI N/A
- ARTL N/A
- Revenue Growth
- PALI N/A
- ARTL N/A
- 52 Week Low
- PALI $0.60
- ARTL $0.82
- 52 Week High
- PALI $9.09
- ARTL $1.59
- Technical
- Relative Strength Index (RSI)
- PALI 45.23
- ARTL 50.27
- Support Level
- PALI $0.65
- ARTL $0.82
- Resistance Level
- PALI $0.77
- ARTL $1.40
- Average True Range (ATR)
- PALI 0.05
- ARTL 0.11
- MACD
- PALI 0.02
- ARTL 0.02
- Stochastic Oscillator
- PALI 70.59
- ARTL 23.10
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About ARTL Artelo Biosciences Inc.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.